Summary
Certara Outlines AI Push, Cost Cuts and New Growth Engines at Jefferies Conference
Certara NASDAQ: CERT executives outlined the company's strategic realignment, artificial intelligence initiatives and cost priorities during a discussion at Jefferies' 2026 Global Healthcare Conference, with newly appointed Chief Executive Officer Jon Resnick saying the company is focused on creating clearer growth engines and improving execution.
Certara, Inc. (CERT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Certara, Inc. (CERT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Certara, Inc. (CERT) Q1 2026 Earnings Call Transcript
Certara, Inc. (CERT) Q1 2026 Earnings Call Transcript
Certara, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TMB Timothy M. Bidwell Hazlett, BURT & WATSON Inc. | 100 | $1,171 | $702.5 | -$468.5 | -40.01% |
| CE Curtis Ellergodt Rothschild Investment LLC | 31 | $273 | $217.77 | -$55.23 | -20.23% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 500 | $4,405 | $3,480.45 | -$924.55 | -20.99% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 226,968 | $1.53M | $1.59M | $60,357.58 | 3.95% |
 Point72 Asset Management LP Point72 Asset Management LP | 1.12M | $6.38M | $7.69M | $1.31M | 20.55% |
Certara, Inc. (CERT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Certara, Inc. ever had a stock split?
Certara, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jon Resnick CEO | NASDAQ (NGS) Exchange | 15687V109 CUSIP |
| US Country | 1,487 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Certara, Inc., with its subsidiaries, operates globally to deliver software products and technology-enabled services tailored for biosimulation applications in various stages of drug discovery and development. Specializing in model-informed drug development, their offerings span across biosimulation for pharmacokinetics and pharmacodynamics prediction, regulatory submissions, and market access. Founded in 2008, Certara capitalizes on its profound expertise to serve a wide spectrum of clients, including life sciences and biopharmaceutical companies, research organizations, academic institutions, and regulators across the United States and internationally. The company’s headquarters are located in Princeton, New Jersey, reflecting its deep commitments to innovation and excellence in the biosimulation domain.
Products and Services
- Simcyp Simulator
- Simcyp Biopharmaceutics
- Simcyp Secondary Intelligence
- Phoenix WinNonlin
- Phoenix Hosted
- Phoenix NLME
- Pirana Modeling Workbench
- Pinnacle 21
- Pinnacle 21 Data Exchange
- Metadata Repository
A mechanistic biosimulation platform designed to facilitate the investigational new drug and translational stages by allowing predictions of pharmacokinetics and pharmacodynamics through a comprehensive mechanistic approach.
This tool is employed to identify and refine drug formulations by leveraging advanced biosimulation techniques, ensuring enhanced drug delivery and efficacy.
Integrates toxicology with quantitative analysis of molecular networks and biological changes, aiding in the detection of drug toxicity and adverse drug reactions efficiently.
Offers non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic modeling capabilities, marking it as a pivotal platform for various pharmacological research phases.
Provides users with a secure and validated Certara Amazon Web Services workspace, enabling streamlined drug development processes in a cloud-based environment.
A cutting-edge software for population modeling and simulation, emphasizing nonlinear mixed effects models to support complex pharmacological analyses.
A comprehensive suite designed for advanced pharmacometrics, providing tools for modeling, simulation, and graphical analysis to streamline pharmacological research.
A cloud platform that automates, standardizes, and validates clinical data, ensuring regulatory compliance and efficiency in drug development workflows.
Facilitates the definition of data standards and specifications, encouraging uniformity and precision in clinical data management.
Allows for controlled and standardized data to inform study design, promoting efficiency and effectiveness across the drug development spectrum.
